Drugs / OP-3136
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06784193 | Dec 2024 → May 2027 expected | castration-resistant prostate carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma, progesterone-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Olema Pharmaceuticals, Inc. | Results Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting olema.com ↗
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. |
| 2026-04-17 | Olema Pharmaceuticals, Inc. | Results Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting olema.com ↗
Combining OP-3136 with palazestrant drives synergistic anti-tumor activity in in vivo ER+/HER2- breast cancer models, which is mediated by suppression of cell-cycle and estrogen receptor-driven oncogenic signaling processes. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-26 | Olema Pharmaceuticals, Inc. | Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer olema.com ↗ |
| 2026-05-21 | Olema Pharmaceuticals, Inc. | Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting olema.com ↗ |
| 2026-04-21 | Olema Pharmaceuticals, Inc. | Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting olema.com ↗ |
| 2026-04-17 | Olema Pharmaceuticals, Inc. | Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting olema.com ↗ |
| 2026-03-17 | Olema Pharmaceuticals, Inc. | Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting olema.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OP-3136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06784193 ↗ |
| Action | Inhibit | “Selective inhibitor of HAT enzymes KAT6A and KAT6B” NCT06784193 ↗ |
| Route | Oral | “administered orally once daily” NCT06784193 ↗ |
| Target | KAT6A | “Selective inhibitor of HAT enzymes KAT6A and KAT6B” NCT06784193 ↗ |
| Target | KAT6B | “Selective inhibitor of HAT enzymes KAT6A and KAT6B” NCT06784193 ↗ |